Advanced

PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery

Andersson, K. E. LU (2018) In British Journal of Pharmacology
Abstract

The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases. Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first-line therapy for erectile dysfunction (ED). The success of sildenafil in the treatment of ED stimulated research in the field of PDE5 inhibition and led to many new applications, such as treatment of lower urinary symptoms, and pulmonary arterial hypertension, which are now approved indications. However, PDE5 inhibitors have also been used in several other disorders not discussed in this review, and the fields of clinical use are increasing. In the present review, the pharmacological... (More)

The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases. Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first-line therapy for erectile dysfunction (ED). The success of sildenafil in the treatment of ED stimulated research in the field of PDE5 inhibition and led to many new applications, such as treatment of lower urinary symptoms, and pulmonary arterial hypertension, which are now approved indications. However, PDE5 inhibitors have also been used in several other disorders not discussed in this review, and the fields of clinical use are increasing. In the present review, the pharmacological basis of the NO/cGMP pathway and the rationale and clinical use of PDE5 inhibitors in different diseases are discussed.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
British Journal of Pharmacology
publisher
The British Pharmacological Society
external identifiers
  • scopus:85045898772
ISSN
0007-1188
DOI
10.1111/bph.14205
language
English
LU publication?
yes
id
d30e8ccc-ba95-4c2f-abb0-4cd02dccd005
date added to LUP
2018-05-04 12:41:01
date last changed
2018-08-12 04:43:56
@article{d30e8ccc-ba95-4c2f-abb0-4cd02dccd005,
  abstract     = {<p>The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases. Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first-line therapy for erectile dysfunction (ED). The success of sildenafil in the treatment of ED stimulated research in the field of PDE5 inhibition and led to many new applications, such as treatment of lower urinary symptoms, and pulmonary arterial hypertension, which are now approved indications. However, PDE5 inhibitors have also been used in several other disorders not discussed in this review, and the fields of clinical use are increasing. In the present review, the pharmacological basis of the NO/cGMP pathway and the rationale and clinical use of PDE5 inhibitors in different diseases are discussed.</p>},
  author       = {Andersson, K. E.},
  issn         = {0007-1188},
  language     = {eng},
  month        = {04},
  publisher    = {The British Pharmacological Society},
  series       = {British Journal of Pharmacology},
  title        = {PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery},
  url          = {http://dx.doi.org/10.1111/bph.14205},
  year         = {2018},
}